Astonea Labs Ltd Stock Price Today (NSE: ASTONEALAB)

Astonea Labs Ltd

ASTONEALABPharmaceuticals
255.2013.10 (4.88%)
Market Closed

Fundamental Score

...

Astonea Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Astonea Labs Ltd share price today is 255.20, down 4.88% on NSE/BSE as of 17 June 2026. Astonea Labs Ltd (ASTONEALAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 157.67 (Cr). The 52-week high for ASTONEALAB share price is 273.95 and the 52-week low is 118.00. At a P/E ratio of 33.98x, ASTONEALAB is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 44.66% and a debt-to-equity ratio of 0.73.

Astonea Labs Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
255.20
Low
130.05
Volume
35.3K
Change
+44.51%

Astonea Labs Ltd share price chart: 44.51% return over the past month. 52-week high ₹273.95, 52-week low ₹118.00.

Astonea Labs Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
237.00273.95237.00273.9515.00K (Cr)
232.00238.00230.55238.0011.00K (Cr)
229.00231.00229.00230.556.00K (Cr)
234.95234.95226.10230.5019.00K (Cr)
230.10233.10229.00229.0026.00K (Cr)
230.00235.95217.00231.0028.00K (Cr)
200.00228.00200.00227.0022.00K (Cr)
185.00198.00185.00197.6513.00K (Cr)
185.00185.00185.00185.002.00K (Cr)
182.95183.00182.00182.004.00K (Cr)

Astonea Labs Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
232.00273.95230.55273.95+18.08%
160.00235.95130.05230.55+44.09%
150.00165.00150.00160.05+6.70%
158.50159.50145.00153.10-3.41%
152.50160.00151.50158.50+3.93%
154.00160.00150.00156.00+1.30%
150.20163.95137.00163.50+8.85%
150.00161.95118.00150.00+0.00%
164.90165.00138.05150.00-9.04%
173.55180.00161.00161.00-7.23%
169.95183.40146.15174.80+2.85%
148.50185.00143.00164.15+10.54%

AI Research Briefing

Powered by Gemini · 2026-04-08

Astonea Labs is a micro-cap play fueled by related party transactions, making it a governance risk with limited organic growth.

Research Confidence
6.0/10Moderate
OPERATOR-DRIVENPrice is down 15.06% over the last 3 months.P/E of 33.98x is slightly expensive compared to the industry P/E of 31.77x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Astonea Labs completed the acquisition of a 25.74% stake in Damaira Pharmaceuticals for , utilizing reallocated IPO proceeds. This acquisition was approved at an Extraordinary General Meeting (EGM) on March 27, 2026, where shareholders also approved material related party transactions worth for FY 2026-27.

CORE STORY (THE REAL GAME)

Why Now
  • Completed Damaira Pharma acquisition for ₹6.25 crore
  • Approved ₹415 crore in related party transactions for FY27
  • Shareholders approved new Articles of Association
Potential Catalysts
  • Successful integration of Damaira Pharma
  • Significant order wins outside of related party transactions
  • Improved quarterly earnings demonstrating organic growth
Key Risks
  • Micro/SME cap exposes to liquidity risk
  • Heavy reliance on related party transactions raises governance concerns
  • YoY Profit down -33.33%
Institutional Activity

FII and DII have decreased their holdings by 5.5% and 4.2% respectively.

Macro Context

Indian pharmaceutical exports are growing, but US Pharma Tariff 2026 is a potential headwind.

Order Book / Expansion

Astonea Labs completed the acquisition of a 25.74% stake in Damaira Pharmaceuticals for ₹6.25 crore.

Cash Flow Quality

No Free Cash Flow data available.

3–6 Month Outlook

Astonea's future hinges on successful integration of Damaira and the ability to generate organic growth beyond related party transactions. Expect volatility due to micro-cap nature.

Primary Thesis Risk

Over-reliance on related party transactions poses a significant governance risk and limits organic growth potential.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Excellent

Return on Equity (ROE)

44.66%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

19.74%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Astonea Labs Ltd Valuation Check

Poor

Price to Earnings (P/E)

33.98x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

72.30%

% shares held by company founders/management

Poor

FII Holding

2.51%

% shares held by foreign institutional investors

Poor

DII Holding

0.35%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-33.33%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

40.24%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.73x

Total debt ÷ equity. Below 0.5 = financially healthy

Good

Interest Coverage Ratio

2.93x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Astonea Labs Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ASTONEALAB across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Strong Return on Equity (44.66%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (19.74%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Revenue Growth (40.24%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Balanced Promoter Holding (72.30%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Profit Decline Concern (-33.33%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Limited Institutional Interest (FII+DII: 2.86%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Astonea Labs Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Astonea Labs Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
31.6/100
255
₹157.67
34.0
Average
44.66%
Excellent
19.74%
Good
0.7
Good
0.00%
65.2/100
1882
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4460
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1335
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2287
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2493
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Astonea Labs Ltd Quarterly Performance

Latest quarterly metrics for ASTONEALAB — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

40.24%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-33.33%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Astonea Labs Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for ASTONEALAB — calculated from daily price history

91RSI 14
Overbought — RSI 91

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
168
▲ Price above SMA 50 — Short-term bullish
SMA 200
163
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
27K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Astonea Labs Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Astonea Labs Ltd (ASTONEALAB) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Astonea Labs Ltd

About ASTONEALAB (Astonea Labs Ltd)

Astonea Labs Ltd is a dynamic pharmaceutical company dedicated to improving global health and well-being through the development, manufacturing, and distribution of high-quality ph...armaceutical and cosmetic products. Driven by innovation and a commitment to excellence, ASTONEALAB meticulously formulates and produces a diverse portfolio of medicines and personal care solutions designed to meet the evolving needs of patients and consumers worldwide. Our unwavering focus on research and development ensures that we remain at the forefront of scientific advancements, constantly exploring new therapeutic possibilities and pushing the boundaries of product efficacy and safety. ASTONEALAB strives to be a trusted partner for healthcare professionals and individuals seeking reliable and effective solutions for a healthier and more vibrant life. ASTONEALAB's product range encompasses a broad spectrum of therapeutic areas, addressing various health concerns and enhancing the quality of life. We offer a comprehensive selection of pharmaceutical products, including essential generic medications, over-the-counter remedies, specialized therapies targeting specific conditions, and innovative nutraceuticals designed to support overall wellness. Furthermore, ASTONEALAB's commitment to beauty and personal care is reflected in our extensive line of cosmetic products, which includes advanced skincare formulas, revitalizing haircare solutions, and age-defying treatments. Our dedication to quality extends across all product categories, ensuring that every item bearing the ASTONEALAB name meets the highest standards of purity, potency, and efficacy. ASTONEALAB operates with a global vision, extending its reach to serve diverse markets and communities around the world. We are committed to fostering strong partnerships with healthcare providers, distributors, and other stakeholders to ensure that our products are readily accessible to those who need them most. Through strategic collaborations and a robust distribution network, ASTONEALAB is expanding its presence in both established and emerging markets, bringing innovative healthcare solutions to a wider audience. We remain steadfast in our mission to make a positive impact on the health and well-being of individuals and communities worldwide, guided by our core values of integrity, innovation, and unwavering commitment to quality.

Company Details

Symbol:ASTONEALAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Ashish Gulati
MD & Director
Ms. Pooja Singh
Executive Director
Mr. Sumit Kumar
Chief Financial Officer

ASTONEALAB Share Price: Frequently Asked Questions

What is the current share price of Astonea Labs Ltd?

Astonea Labs Ltd (ASTONEALAB) trades at ₹255.20 on NSE and BSE. Market cap ₹157.67 (Cr). Educational data only.

What is the P/E ratio of Astonea Labs Ltd?

Astonea Labs Ltd has a P/E of 33.98x vs industry average 31.77x.

What is the Bull Run score for Astonea Labs Ltd?

Astonea Labs Ltd has a Bull Run score of 31.6/100 based on 25+ financial parameters.

Does Astonea Labs Ltd pay dividends?

Astonea Labs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Astonea Labs Ltd?

Astonea Labs Ltd has ROE of 44.66%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Astonea Labs Ltd?

Astonea Labs Ltd has debt-to-equity of 0.73.

Is Astonea Labs Ltd a good investment?

Bull Run gives Astonea Labs Ltd a score of 31.6/100. This is not investment advice — consult a SEBI-registered advisor.